Agenus to Report Fourth Quarter and Year-End 2011 Financial Results on March 5, 2012; Conference Call to Follow
February 29, 2012 10:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its fourth quarter and full-year financial results before the market opens on March 5, 2012.
Agenus...
Agenus to Present at BIO CEO & Investor Conference
February 06, 2012 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Feb. 6, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be...
Agenus to Present at OneMedForum San Francisco 2012
January 04, 2012 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be...
Agenus and ChemRar Enter Into Agreement in the Area of Personalized Cancer Vaccines
December 19, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass. and MOSCOW, Dec. 19, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop treatments for cancers and infectious diseases, and NewVac LLC (a...
Agenus Vaccine for Brain Cancer Highlighted at Current State of the Art Session at the Annual Society for Neuro-Oncology (SNO) Meeting
November 16, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 16, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today that Dr. Michael Sughrue, incoming Director of the Comprehensive Brain Tumor Center, University of...
Agenus Reports Third Quarter 2011 Financial Results and Corporate Updates
October 27, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today its results for the third quarter and nine months ended September 30, 2011. The company reported a net loss...
Agenus to Report Third Quarter Financial Results on October 27, 2011; Conference Call to Follow
October 20, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 20, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its third quarter financial results before the market opens on October 27, 2011.
Agenus executives will...
Positive Results Shown With Agenus' QS-21 Stimulon(R) Adjuvant in Phase 3 Trial of GlaxoSmithKline's Malaria Vaccine
October 18, 2011 13:00 ET
|
Agenus Inc.
First time a QS-21 containing vaccine has demonstrated efficacy in a Phase 3 trial
QS-21 Stimulon® adjuvant currently being studied in 15 indications
o including...
Agenus to Present at NewsMakers in the Biotech Industry Conference
October 18, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 18, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be...
Agenus Compliant With NASDAQ Listing Requirements
October 17, 2011 13:10 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 17, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that it has received notice from the NASDAQ Listing Qualifications Panel (the "Panel") that the Company...